Moderna Shares Plummet Following Leak of Phase 3 Melanoma Vaccine Data
What happened
Moderna shares fell as much as 25 percent after leaked Phase 3 trial data for its melanoma vaccine showed results that met but did not exceed expectations.
The Context
- Data Leak: The Phase 3 trial results were prematurely disclosed, breaching an embargo ahead of the ESMO Congress, leading to chaotic trading.
- Market Reaction: Despite a clinically meaningful 42 percent reduction in recurrence risk, the stock experienced a classic 'sell-the-news' reaction from investors.
- Future Implications: Analysts are now focused on potential regulatory filings in 2027 and the broader implications for Moderna's oncology pipeline.
The Number
— the market value erased from Moderna in a single trading session due to the data reaction, underscoring the financial stakes involved in biotech investments.
Takeaway
As the investigation into the data leak unfolds, keep an eye on how this impacts future regulatory filings and investor sentiment in the biotech sector.
Editor-curated FT homepage stories spanning markets, business, world, and opinion.
"The Financial Times is a globally respected business publication with a centrist/center-left tone and strong markets focus."
— A47 Editor
Moderna shares sink after leaked cancer data missed expectations
Moderna's shares experienced a significant decline after the company announced that its melanoma vaccine treatment, which reduced the risk of recurrence or death by 58%, did not meet Wall Street's high expectations. This news led to a drop in investo...
Stock market news, investing ideas, and trading analysis.
"TheStreet provides market news and retail-investor-focused analysis."
— A47 Editor
Moderna stock’s 17% slump was a ‘sell the news’ event, analyst says
Moderna's stock experienced a significant 17% decline following the leak of trial data for its personalized mRNA cancer vaccine, developed in collaboration with Merck, which showed promising results but failed to meet Wall Street's high expectations.
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
Moderna shares plunged after details from a closely guarded mRNA-based cancer vaccine study were shared on social media
Moderna's shares experienced a significant decline after confidential details from a study on its mRNA-based cancer vaccine were leaked on social media ahead of an anticipated conference. The study was expected to provide critical insights into the v...
U.S. business news, corporate developments, and economy.
"The Wall Street Journal is respected for deep financial and economic reporting with a center-right editorial perspective."
— A47 Editor
Moderna’s Stock Plummets After Cancer-Vaccine Data Shared on Social Media
Moderna's stock experienced a significant decline of up to 25% following the unauthorized sharing of data from a closely guarded study regarding its personalized mRNA cancer vaccine. This data was expected to be formally presented at an upcoming conf...
Global business headlines with AI angles.
"General business outlet that frequently covers AI."
— A47 Editor
Details of Moderna's Breakthrough Cancer Vaccine Got Leaked. Its Stock is Plunging.
Moderna's stock plummeted by up to 25% following the leak of data regarding its experimental cancer vaccine, despite the information being more favorable than Wall Street's expectations. This unexpected decline raises concerns about investor confiden...
Business, investment, entrepreneurship, leadership, and innovation.
"Forbes is known for its coverage of business leaders, market trends, and entrepreneurial ventures with a pro-business editorial stance."
— A47 Editor
Moderna Stock Plunges 25% After Possible Cancer Vaccine Data Leak
Moderna's stock plummeted by 25% following a potential data leak regarding its personalized cancer vaccine, marking a significant downturn after a previously strong stock rally in 2026 driven by optimism about the vaccine's prospects.